Trial Profile
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Lewy body disease
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 01 Nov 2022 According to Eisia media release, treatment with this drug showed a trend toward improvement in cognitive function, and this result is consistent with the results of the clinical trial at the time of approval of the drug; Therefore, it was concluded that the approved label (dose and administration) and package insert should be appropriately revised (Category 2). The condition of the approval was lifted as of the date of receipt of the reexamination results.
- 01 Nov 2022 According to Eisia media release, the reexamination based on postmarketing studies, including the results of Study 419, stated that at present, the evaluation of clinical function in DLB using CIBIC-Plus is not always sufficiently established as an evaluation method, and it is difficult to comprehensively evaluate the efficacy of this drug for DLB, although efficacy was seen in some patients.
- 01 Nov 2022 Primary endpoint (Clinicians Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC-plus)) has not been met as per Eisai Media Release